Phase III Analyses Prompt Partial Clinical Hold On Oncopeptides' Melflufen Studies
OCEAN OS Data Favors Active Comparator
Oncopeptides AB’s melflufen (Pepaxto) has met the primary PFS endpoint in the Phase III OCEAN study, designed to extend its reach into earlier-stage multiple myeloma patients, but overall survival data favors the comparator in patient subgroups, and melflufen in others, leading to regulators pausing clinical trials to review the results.
